Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
64Cu-Plerixafor PET imaging of CXCR4 in cancer
NCT02069080Phase 1Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Feb 2014
- Primary completion
- Jul 2018
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 64Cu-plerixafor in cancer, sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Uptake of 64Cu-plerixafor in target lesion vs surrounding non-tumor tissue at 2 years. Started Feb 2014; status: terminated.
02
Drugs
64Cu-plerixafor
03
Conditions
cancer
Beyond the preview
Go deeper on NCT02069080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02069080.